That's exactly right. When we coordinate bioproduction, along with the investment in the regulatory dossier required to submit a clinical trial application to Health Canada, that's where we're able to support these clinical outcomes. So it's absolutely essential, and it requires funding.
In fact, this type of funding isn't currently managed very well. That's why BioCanRx was created in 2015. It was created to bridge what is known as “the valley of death” that exists between discovery and these early-stage clinical trials, such as phase 1 and phase 1/2 trials.